We are committed to finding a cure for WM.

Did you know?

 

Welcome to the Waldenstrom’s Macroglobulinemia Foundation of Canada (WMFC)

If you have been diagnosed with Waldenstrom’s Macroglobulinemia (WM) or care for someone who has, welcome to the WMFC family of WM patients, caregivers, friends and relatives. We are a community providing support, research and information on WM.

Sign up for our newsletter below to receive updated information.

 

Information for the newly diagnosed

New Non-Live Shingles Vaccine (Shingrix)

Please click on the link below to find out more information about this new vaccine   Shingrix.  A pharmacist explains the differences between Shingrix and Zostavax (live vaccine for shingles)Read More

Article: 2767 Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom’s Macroglobulinemia

Paper: Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom’s Macroglobulinemia   Source: https://ash.confex.com/ash/2017/webprogram/Paper105275.html   Program: Oral and Poster Abstracts Session: 623. Mantle Cell, Follicular, and Other IndolentRead More

Article: Primary Endpoints Met in Phase 3 of Imbruvica with Rituximab in Waldenstom’s Macroglobulinemia

DECEMBER 05, 2017 Mathew Shanley   Primary Endpoints Met in Phase 3 of Imbruvica with Rituximab in Waldenstom’s Macroglobulinemia   A Phase 3 of Imbruvica (ibrutinib) in combination with RituxanRead More

Article: Ibrutinib Effective As First-line Therapy for Waldenstrom Macroglobulinemia

Ibrutinib Effective As First-line Therapy for Waldenstrom Macroglobulinemia – Print Article – Cancer Therapy Advisor Ibrutinib is a safe and highly active treatment among previously untreated patients with Waldenstrom macroglobulinemiaRead More

Subscribe to our newsletter